CRNDE, a Potential Therapeutic Target in Human Diseases

Long non-coding RNAs (lncRNAs) are RNA molecules exceeding 200 nucleotides in length with minimal or no protein-coding potential. However, a large number of lncRNAs have been discovered as research has progressed, and the traditional view of these noncoding RNAs does not appear to be entirely correct. Recent research has also unveiled their significant roles in various biological processes, spotlighting lncRNAs' importance. The oncogenic lncRNA, Colorectal tumor Differentially Expressed (CRNDE), is prominently studied in cancer contexts. One study found that the modulation of CRNDE expression led to an improvement in the median survival of cancer patients, extending it from 19.2 months to 32.5 months. Nonetheless, CRNDE also exhibits deregulated expression in non-malignant diseases, influencing their pathologies and serving as a potential biomarker and therapeutic target. For example, in the context of COVID-19, with CRNDE serving as a diagnostic indicator, its diagnostic accuracy attains a value as high as 0.889. This review examines CRNDE's expression in specific human diseases, including non-cancerous and cancerous conditions, its impact on disease progression, the underlying mechanisms, and recent therapeutic approaches.